-
Rare mountain gorilla twins born in DR Congo: park authorities
-
Ex-midwife enthroned as first female Archbishop of Canterbury
-
AC Schnitzer: When Iconic Tuners Fall Silent
-
Senegal lodge appeal to Court of Arbitration for Sport over AFCON final decision
-
South Africa seal T20 series win in New Zealand
-
Study links major polluters to big climate damages bill
-
Ex-Google chief Matt Brittin made new BBC director-general
-
Iran likely behind attacks sowing fear among Europe's Jews: experts
-
'Relieved' McGrath claims career first crystal globe in slalom
-
US ski star Shiffrin wins overall World Cup title for sixth time
-
Trump names tech titans to science advisory council
-
Mideast war sparks long queues at Kinshasa petrol stations
-
US TV star details 'agony' over mother's disappearance
-
Tehran receives US plan to end Mideast war, as Iran fires at US carrier
-
Aviation, tourism, agriculture... the economic sectors hit by the war
-
Iran fires at US carrier as backchannel diplomacy aims to end war
-
Salah's long goodbye brings curtain down on golden era for Liverpool
-
Monaco: city of vice and a few virtues
-
AI making cyber attacks costlier and more effective: Munich Re
-
Defying Israeli bombs, Lebanese hold out in southern city of Tyre
-
War-linked power crunch pushes Sri Lanka to four-day week
-
Hungary says will phase out gas deliveries to Ukraine
-
Oil prices tumble, stocks rally on Mideast peace hopes
-
Maybach: Between Glory and a Turning Point
-
German business morale falls as war puts recovery on ice: survey
-
Labubu maker Pop Mart's shares fall 23% despite surging earnings
-
ECB won't be 'paralysed' in face of energy shock: Lagarde
-
Iran hits targets across Middle East after Trump signals talks progress
-
McEvoy says best is to come after breaking long-standing swim record
-
Goat vs gecko: A tiny Caribbean island faces wildlife showdown
-
Japan PM asks IEA chief to prepare additional 'coordinated release' of oil
-
Hungary's hard-pressed LGBTQ people say Orban exit is only half battle
-
Belarus leader visits North Korea for first time
-
'No heavier burden': the decades-long search for Kosovo war missing
-
Exotic pet trade thrives in China despite welfare concerns
-
Iran fires missile salvo after Trump signals progress in talks
-
BTS concert drew 18.4 million viewers, says Netflix
-
OSCE's 'chaotic' Ukraine evacuation put staff at risk: leaked report
-
Top WTO official sounds fertiliser warning over Middle East war
-
France and Brazil weigh up World Cup prospects in glamour friendly
-
Italy hoping to end World Cup pain as play-offs loom
-
Dirty diapers born again in Japan recycling breakthrough
-
Verstappen's Japan GP win streak under threat as Mercedes dominate
-
Crude tumbles, stocks rally on hopes for Iran war de-escalation
-
Gauff outlasts Bencic to reach Miami semi-finals
-
'Hero' Australian dog who saved 100 koalas retires
-
Underdogs chase World Cup berths in Mexico playoff tournament
-
Pope heads to tiny Catholic Monaco
-
Meet the four astronauts set to voyage around the Moon
-
Artemis 2 Moon mission: a primer
US regulator approves new generic abortion pill, conservatives outraged
US regulators have approved an additional generic version of the abortion pill mifepristone, a normally routine move that nevertheless angered anti-abortion activists.
A number of conservative figures and anti-abortion groups decried the regulatory step, with the institution Students for Life Action calling it "a stain on the Trump presidency."
The drugmaker Evita said on its website the US Food and Drug Administration had this week approved the company's generic tablet, which is currently approved to end pregnancies up to 70 days of gestation.
The medication is used in the majority of abortions in the United States, and also routinely used for managing early miscarriage.
The FDA originally approved mifepristone in 2000, and another generic already exists.
Approvals of additional generics are typically routine.
But Marjorie Dannenfelser, president of the organization Susan B. Anthony Pro-Life America, called the approval "reckless" and "unconscionable" in a statement Thursday.
Senator Josh Hawley, a Republican from Missouri, said on X he had "lost confidence" in FDA leadership while former vice president Mike Pence posted it was "a complete betrayal of the pro-life movement that elected President Trump."
Pence also called for the dismissal of Robert F. Kennedy Jr, Trump's controversial health chief.
The ruckus comes weeks after Kennedy and FDA Commissioner Marty Makary reportedly delivered a letter to 22 Republican attorneys general saying the FDA was conducting a new review of mifepristone's safety.
Abortion rights organizations have dubbed that a blatant attempt to undermine health care access, and a coalition of attorneys general from more than a dozen Democratic-led states vowed to protect availability of the drug.
The American Medical Association has called the prescription drug "exceedingly safe and effective" and said restricting access to mifepristone would "jeopardize public health."
That take echoes the positions of many leading medical institutions.
Mifepristone, which prevents pregnancy progression, is generally used in combination with misoprostol, which empties the uterus.
O.Karlsson--AMWN